Discounted Cash Flow

Autolus Therapeutics Plc. ADR

AUTL · Based on 10 years of SEC filings

DCF estimate unavailable — No positive free cash flow in recent history — company has not generated positive FCF

Average annual growth rates

Metric 10-Year 5-Year 3-Year
Sales
Free Cash Flow
Average (FCF & NI)
Net Income
Dividends

Average annual growth is the mean year-over-year change across each period.

Endpoint CAGR (better for long term trend)

Metric 10-Year 5-Year 3-Year
Sales
Free Cash Flow
Average (FCF & NI)
Net Income

Endpoint CAGR is the compound annual rate from the first to last year in each period.

Projections use average year-over-year growth. Change this in Settings.

Projected growth rate

Free cash flow growth
10-year: — 5-year: — 3-year: —
Averaged growth (FCF & NI)
10-year: — 5-year: — 3-year: —
Net income growth
10-year: — 5-year: — 3-year: —
Sales growth (not added to calculations)
10-year: — 5-year: — 3-year: —

Click a greyed-out slider to switch metrics. Slide between the 10-year, 5-year, and 3-year historic growth rates for FCF, net income, or their average.

%
%

Historical inputs (10 fiscal years)

YEAR Sales Net Income Free Cash Flow Net Margin EPS (diluted)
2016 $75.0k $-12.6m $-11.7m -16733.3% $-1.26
2017 $84.0k (12.0%) $-19.7m (-57.2%) $-19.2m (-64.4%) -23484.5% (-40.3%) $-1.43 (-13.5%)
2018 $1.4m (1575.0%) $-44.8m (-126.9%) $-40.7m (-111.4%) -3180.6% (86.5%) $-1.42 (0.7%)
2019 $2.9m (106.7%) $-123.8m (-176.8%) $-119.8m (-194.7%) -4258.9% (-33.9%) $-2.88 (-102.8%)
2020 $536.0k (-81.6%) $-142.1m (-14.7%) $-132.4m (-10.5%) -26510.1% (-522.5%) $-2.76 (4.2%)
2021 $262.0k (-51.1%) $-142.1m (-0.0%) $-126.7m (4.3%) -54235.1% (-104.6%) $-1.97 (28.6%)
2022 $1.7m (551.9%) $-148.8m (-4.7%) $-123.1m (2.8%) -8714.2% (83.9%) $-1.57 (20.3%)
2023 $0 (-100.0%) $-208.4m (-40.0%) $-156.6m (-27.1%) $-1.20 (23.6%)
2024 $10.1m $-220.7m (-5.9%) $-228.3m (-45.8%) -2180.5% $-0.86 (28.3%)
2025 $75.4m (644.9%) $-287.5m (-30.3%) $-302.6m (-32.5%) -381.4% (82.5%) $-1.08 (-25.6%)

Base FCF: (latest fiscal year)

Discount rate: %

Terminal growth:

Projection period: years

Alt A decline yrs:

Alt B total yrs:

Projected cash flows

Year Projected cash flow Discount Factor Present Value

PV of projected FCF:

Terminal FCF:

Terminal value:

PV of terminal value:

Enterprise value (DCF):

DCF price per share:

Current price:

Alternative DCF Models

Model Fair Value Upside PV(FCFs) PV(Terminal) Total Years
Standard (10yr→TV) 10 + TV
Alt A (Gradual Decline)
Alt B (30yr Hard Stop) N/A

This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.

+ 10YR Financials Balance Sheet (10YR) Cash Flow (10YR) DCF Model

No positive free cash flow in recent history — company has not generated positive FCF

Once the company meets all DCF eligibility criteria (sufficient history, profitability, growth trends), an estimate will become available automatically. No action is needed.